SG11202004128TA - Acid-mediated assay for analyzing ligand-drug conjugates - Google Patents

Acid-mediated assay for analyzing ligand-drug conjugates

Info

Publication number
SG11202004128TA
SG11202004128TA SG11202004128TA SG11202004128TA SG11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA SG 11202004128T A SG11202004128T A SG 11202004128TA
Authority
SG
Singapore
Prior art keywords
acid
drug conjugates
mediated assay
ligand
analyzing
Prior art date
Application number
SG11202004128TA
Inventor
Stephen Alley
Russell Sanderson
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11202004128TA publication Critical patent/SG11202004128TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N2030/042—Standards
    • G01N2030/045—Standards internal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G01N2030/067—Preparation by reaction, e.g. derivatising the sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202004128TA 2017-11-22 2018-11-20 Acid-mediated assay for analyzing ligand-drug conjugates SG11202004128TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590169P 2017-11-22 2017-11-22
PCT/US2018/062100 WO2019104084A1 (en) 2017-11-22 2018-11-20 Acid-mediated assay for analyzing ligand-drug conjugates

Publications (1)

Publication Number Publication Date
SG11202004128TA true SG11202004128TA (en) 2020-06-29

Family

ID=66632149

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004128TA SG11202004128TA (en) 2017-11-22 2018-11-20 Acid-mediated assay for analyzing ligand-drug conjugates

Country Status (11)

Country Link
US (1) US20200363425A1 (en)
EP (1) EP3713588A4 (en)
JP (1) JP2021504695A (en)
KR (1) KR20200090195A (en)
CN (1) CN111344001A (en)
AU (1) AU2018370859A1 (en)
CA (1) CA3082549A1 (en)
IL (1) IL274656A (en)
MX (1) MX2020005319A (en)
SG (1) SG11202004128TA (en)
WO (1) WO2019104084A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230022980A1 (en) * 2019-09-04 2023-01-26 Seagen Inc. Double-digestion assay for analyzing ligand-drug conjugates
US11930499B2 (en) * 2021-04-07 2024-03-12 Tencent America LLC Network monitoring in service enabler architecture layer (SEAL)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683676A4 (en) * 1993-02-02 1998-09-30 Neorx Corp Directed biodistribution of small molecules.
ES2556641T3 (en) * 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease
WO2005050188A1 (en) * 2003-11-21 2005-06-02 Eisai Co., Ltd. Quantification method with the use of isotope-labeled internal standard, analysis system for carrying out the quantification method and program for dismantling the same
CA2678514A1 (en) * 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
GB201213127D0 (en) * 2012-07-24 2012-09-05 Univ Dundee Novel isotopic labelling method
WO2014197754A1 (en) * 2013-06-07 2014-12-11 Pierce Biotechnology, Inc. Absolute quantitation of proteins and protein modifications by mass spectrometry with multiplexed internal standards
KR20240034882A (en) * 2013-10-15 2024-03-14 씨젠 인크. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US9594085B2 (en) * 2014-02-03 2017-03-14 Integrated Diagnostics, Inc. Integrated quantification method for protein measurements in clinical proteomics
JP6412906B2 (en) * 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Compound, linker-drug and ligand-drug complex
US20170315132A1 (en) * 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay

Also Published As

Publication number Publication date
IL274656A (en) 2020-06-30
KR20200090195A (en) 2020-07-28
MX2020005319A (en) 2020-10-01
EP3713588A4 (en) 2021-08-04
CN111344001A (en) 2020-06-26
AU2018370859A1 (en) 2020-06-18
US20200363425A1 (en) 2020-11-19
EP3713588A1 (en) 2020-09-30
JP2021504695A (en) 2021-02-15
CA3082549A1 (en) 2019-05-31
WO2019104084A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
HK1258539A1 (en) Micro-moment analysis
GB2554180B (en) Spectrometric analysis
EP3372985A4 (en) Analysis device
IL259531B (en) Assay device
GB2602212B (en) Spectrometric analysis
GB201611840D0 (en) Alpha-synuclein detection assay
PL3336514T3 (en) Direct analysis sampler
PL3336511T3 (en) Direct analysis sampler
GB201710394D0 (en) Multicolour fluorescence analysis device
GB2551937B (en) Biopsy sample retention mechanism
SG10201601097XA (en) Amplitude-versus-angle analysis for quantitative interpretation
IL266857A (en) Antibody assay
GB201514730D0 (en) Assay device
GB2561879B (en) Spectroscopic analysis
GB2570742B (en) Optical-interference analysis
IL274656A (en) Acid-mediated assay for analyzing ligand-drug conjugates
EP3388830A4 (en) Analysis device
EP3307712A4 (en) Radioiodinated bioconjugation reagents
GB201614152D0 (en) Assay
EP3428633A4 (en) Analysis device
GB2579810B (en) Assay Analysis
GB201605210D0 (en) Assay
GB201514712D0 (en) Assay device
GB2580271B (en) Analysis device
GB201617175D0 (en) Assay